Scientists developed inhalable nanoparticles that carry rifampin, a common tuberculosis drug. The particles have a biodegradable core that holds the drug and a coating that helps them stick to lung immune cells called macrophages.
The particles go to the lungs and are taken up by macrophages where TB bacteria hide. The drug is released slowly so the lung keeps the medicine longer. Because of this, treatment might be needed once a week instead of every day.
Researchers tested the idea in two different mouse models and worked under BSL-3 safety rules. Next they will study combination therapy with other TB antibiotics.
Difficult words
- inhalable — able to be breathed into the lungs
- nanoparticle — a very small particle you cannot seenanoparticles
- biodegradable — able to break down naturally in the body
- macrophage — an immune cell that eats bacteria and debrismacrophages
- tuberculosis — a serious lung disease caused by bacteria
- rifampin — an antibiotic used to treat tuberculosis
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Do you prefer a weekly inhaled treatment or daily medicine? Why?
- Would you be worried about inhalable nanoparticles as a patient? Why or why not?
- Why do you think researchers worked under BSL-3 safety rules?
Related articles
Targeting a brain circuit to reduce opioid relapse
Researchers at Washington State University found that lowering activity in a specific brain connection cut heroin-seeking in a preclinical model. The study identifies a pathway between the prelimbic cortex and the paraventricular thalamus and tests two ways to reduce its activity.
Antibody and EGFR–STAT1 pathway point to new fibrosis treatments
Researchers at Yale found a human antibody that blocks epiregulin and lowers fibrosis markers. They also show EGFR activates STAT1 in fibroblasts, suggesting two treatment paths: block epiregulin or target the EGFR–STAT1 pathway.